Arrowhead Pharmaceuticals, Inc. ARWR
Set alert
As of Nov 2, 10:54 AM ET
- YTD
- -9.29%
- 1 year
- +42.07%
- Open
- 60.55
- Prev close
- 59.90
- Mkt cap
- 8.48B
- Vol
- 245.14K
- Avg vol
- 1.72M
- EPS
- -2.28
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 60.19
- High
- 61.17
- Forward P/E
- -12.03
- Beta
- 1.30
- Short ratio
- 4.41
- Inst. own
- 85.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 24, 2026
- 50-d avg
- 70.34
- 200-d avg
- 71.76
- 1y target
- 107.71
News
-
3 hours ago benzinga.com
Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking…
3 hours ago businesswire.com
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in…
-
6 days ago benzinga.com
Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients…
6 days ago businesswire.com
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial…
1 week ago benzinga.com
Top 3 Health Care Stocks That Could Blast Off In October
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
2 weeks ago defenseworld.net
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the…
2 weeks ago seekingalpha.com
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its…
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
2 weeks ago seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
2 weeks ago marketbeat.com
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central…
2 weeks ago benzinga.com
Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
-
2 weeks ago benzinga.com
Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…
-
2 weeks ago benzinga.com
Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau…
2 weeks ago businesswire.com
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA…
3 weeks ago businesswire.com
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in…
3 weeks ago defenseworld.net
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded…
1 month ago seekingalpha.com
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and…
1 month ago businesswire.com
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
1 month ago benzinga.com
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stocks bucked the selloff.
1 month ago marketbeat.com
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and…
1 month ago marketbeat.com
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
1 month ago benzinga.com
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
1 month ago seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
1 month ago gurufocus.com
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's
1 month ago businesswire.com
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first…
1 month ago seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108
Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
1 month ago fool.com
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.
2 months ago businesswire.com
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
-
2 months ago benzinga.com
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
-
2 months ago benzinga.com
Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a…
-
2 months ago benzinga.com
Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany.
-
2 months ago benzinga.com
Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome
REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.
-
2 months ago benzinga.com
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of…
-
2 months ago benzinga.com
Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026
SNDA to seek approval to expand the approved indication to include patients with severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis,…
-
3 months ago benzinga.com
B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123
B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.
3 months ago benzinga.com
4 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 months ago benzinga.com
Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.
-
3 months ago benzinga.com
Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $100 to $115.
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.
-
3 months ago benzinga.com
Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126
Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.
-
3 months ago benzinga.com
Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.
3 months ago benzinga.com
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat
The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.